Abstracts tagged "clinical trial"

Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad Rovin¹, Elsa Martins², Cary Austin³, Harini Raghu³, Caleb Chan³, Patrick Chang³, Jay Garg³, Valeria Alberton⁴, Mittermayer Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra Palazuelos⁷, Teresa Baczkowska⁸, José Alfaro⁹, Jorge Ravelo-Hernández¹⁰, Richard Furie¹¹, Luís Pinto¹², Eduardo Albiero¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler², Theodore Omachi³, William Pendergraft III³ and Ana Malvar¹⁶, ¹Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³Genentech, Inc., South San Francisco, California, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C., Mexico City, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clinica San Juan Bautista, Unidad de Investigacion en Reumatologia e Inmunologia, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, Great Neck, New York, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Medellín, Colombia, ¹³Sanatorio Allende, Córdoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, Arkansas, ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁶Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: LB21 • ACR Convergence 2025
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Flore Castellan¹, Griffen Mustion², Mei-Kay Wong¹, Kimberly Johansson², Scott Goldberg¹, Yazan Madanat³, Namrata Chandhok⁴, Abhay Singh⁵, David Sallman⁶, Jane Churpek⁷, Curtis Lachowiez⁸, Jennifer Yannucci⁹, Luke Fletcher¹⁰, Matthew Schwede¹¹, Amber Afzal², Yael Kusne¹², Alejandro Marinos¹³, Alexander Coltoff¹⁴, Rickey Myhand¹⁵, Kiran Vij², Rosalyn Marar¹⁶, Hannah Mitchell², Maria Stoentcheva², Giulia Petrone², Kyra Ddungu², Hannah Hartman², Ryan Monahan², Karen Vandervort², Jie Liu², John Cole², Tibor Kovacsovics¹⁷, Hetty Carraway¹⁸, Tian Zhang¹⁹, Stephen Chung³, Geoffrey Uy², Eytan Stein²⁰, Devendra Hiwase²¹, Matthew Walter², Mrinal Patnaik¹⁶, Kelly Bolton²² and David Beck¹, ¹New York University School of Medicine, New York, New York, ²Washington University School of Medicine, Saint Louis, Missouri, ³UT Southwestern Medical Center, Dallas, Texas, ⁴University Miami Miller School of Medicine, Miami, Florida, ⁵Cleveland Clinic, Cleveland, Ohio, ⁶Moffitt Cancer Center, Tampa, Florida, ⁷University of Wisconsin School of Medicine, Madison, Wisconsin, ⁸Oregon Health & Science University, Portland, Oregon, ⁹Low Country Cancer Care, Savannah, Georgia, ¹⁰Willamette Valley Cancer Institute and Research Center, EUgene, Oregon, ¹¹Swedish Health Services, Seattle, Washington, ¹²Mayo Clinic, Phoenix, Arizona, ¹³UTSouthwestern Medical Center, Dallas, Texas, ¹⁴Medical University of South Carolina, Charleston, South Carolina, ¹⁵CovenantOntology & Hematology, Frankfort, Kentucky, ¹⁶Mayo Clinic, Rochester, Minnesota, ¹⁷City of Hope, Goodyear, Arizona, ¹⁸Case Western Reserve University, Cleveland, Ohio, ¹⁹Stanford Medicine, Stanford, California, ²⁰Memorial Sloan Kettering Cancer Center, New York, New York, ²¹Adelaide Medical School, Adelaide, South Australia, Australia, ²²Washington University School of Medicine, Saint Louis, Minnesota
Background/Purpose: Recently, somatic mutations in hematopoietic stem and progenitor cells (HSPCs) have been proposed as a novel mechanism driving systemic inflammation. UBA1 somatic variants in…
Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Andreas Reiff¹, Tadej Avcin², Bernd Jilma³, Peter Korosec⁴, Matthias Weiss-Tessbach³, Christian Schoergenhofer³, Masa Bizjak⁵, Barbara Jenko Bizjan⁶, Barbara Cugalj Kern⁵, Kim Simpfendorfer⁷, Christian Lood⁸, Tyler Artner⁹, Angelene Prasanna¹, Ken Olivier¹, Ghazaleh Gouya¹, Ralph Lambalot⁹, Abdul Hakkim¹ and Tobias Fuchs¹, ¹Neutrolis, Cambridge, Massachusetts, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Medical University of Vienna, Vienna, Austria, ⁴University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, ⁵University Medical Center Ljubljana, Ljubljana, Slovenia, ⁶University of Ljubljana, Ljubljana, Slovenia, ⁷Feinstein Institutes for Medical Research, Manhasset, New York, ⁸University of Washington, Seattle, Washington, ⁹Neutrolis, Cambridge
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…
Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Leslie Crofford¹, Dana Dailey², Barbara Van Gorp², Carol Vance², Andrew Post³, Ruth Chimenti², Ezgi Yarasir², Elizabeth Johnson¹, Kari Vance², Bridget Zimmerman², Fangfang Jiang², David-Erick Lafontant², Maxine Koepp², Dixie Ecklund², Emine Bayman² and Kathleen Sluka², ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²University of Iowa, Iowa City, Iowa, ³Grand Valley State University, Grand Rapids, Michigan
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Philip Mease¹, Frank Behrens², Alan Kivitz³, Edit Drescher⁴, Piotr Klimiuk⁵, Howard Sofen⁶, Nehad Soloman⁷, Shephard Mpofu⁸, Fredrik Frejd⁹ and Peter Taylor¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ²Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ³Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, ⁴Vital Medical Center Rheumatology, Veszprém, Hungary, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, California, ⁷Midwestern University Arizona College of Osteopathic Medicine and Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, ⁸ACELYRIN, INC., Agoura Hills, California, ⁹Affibody Medical AB, Solna, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…
Abstract Number: LB09 • ACR Convergence 2025
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Elisa Dalix¹, Philippe Goupille², Daniel Wendling³, Christian Roux⁴, Jean-Hughes Samon⁵, Olivier Brocq⁶, Anne Tournadre⁷, Arnaud Constantin⁸, Maxime Breban⁹, Gregoire Cormier¹⁰, Tristan Pascart¹¹, Thierry Lequerre¹², Pascal Claudepierre¹³, Eric Lespessailles¹⁴, Benoit Legoff¹⁵, Jeremie Sellam¹⁶, Athan Baillet¹⁷, Thierry Schaeverbeke¹⁸, Stephan Pavy¹⁹, Valerie Devauchelle-Pensec²⁰, Elisabeth Gervais²¹, Laure Gossec²², Corinne Miceli²³, Yves-Marie Pers²⁴, Cedric Lukas²⁵, Renaud Felten²⁶, Beatrice Bouvard²⁷, Amelie Denis²⁸, Emmanuelle Dernis²⁸, Emilie Presles²⁹, Florence Rancon²⁹ and Hubert Marotte³⁰, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Rheumatology and INSERM-CIC¹⁴¹⁵, University Hospital of Tours, EA ⁷⁵⁰¹ GICC, University of Tours, Tours, France, ³Rhumatologie, CHU de Besançon, Besancon, France, ⁴Service de rhumatologie, CHU de Nice, IbV, Université Cote d'Azur, Nice, France, ⁵Service de Rhumatologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France; Université de Reims Champagne-Ardenne, Faculté de Médicine, EA ³⁷⁹⁷, Reims, France, ⁶Rheumatology Department, CHPG Monaco, Monaco, Monaco, ⁷Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸Rheumatology Center, Toulouse University Hospital, Toulouse, France, ⁹INSERM UMR¹¹⁷³, INFLAMEX, Laboratoire d'Excellence, Rheumatology Division, Ambroise Paré Hospital (AP-HP), Paris, France, ¹⁰Rheumatology, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France, ¹¹Department of Rheumatology, Université Catholique de Lille Hôpital Saint Philibert, Lomme, France, ¹²Department of Rheumatology & CIC-CRB ¹⁴⁰⁴, Inserm, PANTHER UMR ¹²³⁴, University of Rouen Normandie, Normandie University, CHU Rouen, Rouen, France, ¹³AP-HP, Henri-Mondor Hospital, Department of Rheumatology, EpiDermE, Université Paris Est Créteil, Créteil, France, ¹⁴Translational Medicine Research Platform, PRIMMO, University Hospital Centre of Orleans, Orleans, France, ¹⁵Nantes Université, ONIRIS, Univ Angers, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR ¹²²⁹, Nantes, France, ¹⁶Rheumatology Department, Sorbonne Université, Saint-Antoine Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Centre de Recherche Saint-Antoine (CRSA) Inserm UMRS-⁹³⁸,, Paris, France, ¹⁷Université Grenoble Alpes, ⁴UMR⁵⁵²⁵, Grenoble, France, ¹⁸Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France, ¹⁹Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicetre, ²⁰Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U¹²²⁷), LabEx IGO, Brest, France, ²¹LITEC, Université de Poitiers, CHU Poitiers, Poitiers, France, ²²Sorbonne Université, AP-HP & EULAR, Paris, France, ²³Immunoregulation Unit, Institut Pasteur, Cochin AP-HP, Paris, France, ²⁴IRMB, University of Montpellier, Inserm U¹¹⁸³, CHU Montpellier, Montpellier, France, ²⁵Rheumatology department, CHU and University of Montpellier, Montpellier, France; UMR UA¹¹ Inserm (IDESP), University of Montpellier, Montpellier, France, ²⁶Service de Rhumatologie, CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France, ²⁷Rhumatologie, Centre Hospitalier Universitaire, Angers, France, ²⁸CH Le Mans, Le Mans, France, ²⁹CHU Saint-Etienne, CIC ¹⁴⁰⁸, Saint-Etienne, France, ³⁰Université Jean Monnet, CHU de Saint-Etienne, CIC ¹⁴⁰⁸, Mines Saint-Etienne, INSERM, SSINBIOSE ¹⁰⁵⁹, Saint-Etienne, France
Background/Purpose: Axial spondyloarthritis (axSpA) is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease-modifying antirheumatic drugs (bDMARDs). Up to…
Abstract Number: LB12 • ACR Convergence 2025
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
Philip Conaghan¹, Bernt Husøy², Cecilie Rovsing³, Sidsel L Boll⁴, Liliana Groppa⁵, Amir Oron⁶, Asger Bihlet⁷, Ali Mobasheri⁸, Tobias Winkler⁹, Dror Mevorach¹⁰, Einat Galamidi¹¹, Lital Weinfeld-Bergman¹², Lior Binder¹² and Oren Hershkovitz¹¹, ¹University of Leeds, Leeds, United Kingdom, ²Sanos Clinic, Herlev, Denmark, ³Sanos Clinic, Gandrup, Denmark, ⁴Sanos Clinic, Vejle, Denmark, ⁵T. Mosneaga Republican Clinical Hospital, Chisinau, Moldova, ⁶Kaplan MC, Rehovot, Israel, ⁷NBCD A/S, Soeborg, Denmark, ⁸University of Oulu, Oulu, Finland, ⁹Charité - Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Hadassah-University Hospital, Jerusalem, Israel, ¹¹Enlivex Therapeutics, Ness Ziona, Israel, ¹²Enlivex Therapeutics, Nes Ziona, Israel
Background/Purpose: OA is a prevalent disabling disease growing globally due to aging populations and rising obesity. In primary OA, the effects of joint tissue damage accumulate with age,…
Abstract Number: 2663 • ACR Convergence 2025
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
David Beck¹, Mael Heiblig², Sinisa Savic³, Marcela ferrada⁴, Arsène Mekinian⁵, Onima Chowdhury⁶, Danielle Hammond⁷, Lachelle D. Weeks⁸, Carmelo Gurnari⁹, Yohei Kirino¹⁰, Sophie georgin-Lavialle¹¹, Sarah A. Buckley¹², Bryan G. harder¹², Sandra Goble¹² and Matthew Koster¹³, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ²Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴University of Maryland, Bethesda, MD, ⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁶Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, ⁸Dana Farber Cancer Institute, Boston, MA, ⁹Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ¹⁰Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹¹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹²Sobi Inc., Waltham, MA, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Treatment poses…
Abstract Number: 2440 • ACR Convergence 2025
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
Abstract Number: 2288 • ACR Convergence 2025
Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)
Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
Abstract Number: 2012 • ACR Convergence 2025
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
ullrich schwertschlag¹, yan yang², Jingfei li³, Roy Wu⁴, adam jin² and William Shi⁵, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Therapeutics, Suzhou, China (People's Republic), ³Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), ⁴Atom Bioscience, San Francisco, CA, ⁵Atom Therapeutics, Newark, CA
Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…
Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Susan Manzi¹, Ian Bruce², Eric Morand³, Richard Furie⁴, Yoshiya Tanaka⁵, Patricia Puzio⁶, Emon Khan⁷, Jenny Wissmar⁸, Michael Song⁹ and Catharina Lindholm¹⁰, ¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁴Division of Rheumatology, Northwell Health, Great Neck, NY, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, ¹⁰BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…

1
2
3
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].